Healthcare Realty Trust Incorpo (HR) Stock Price & How to Invest

Healthcare Realty Trust is a real estate investment trust focused on outpatient medical facilities, primarily medical office buildings leased to health systems, physician groups, and related healthcare tenants, with properties concentrated on or near acute-care hospital campuses. The company became the largest dedicated owner of medical office real estate after its 2022 combination with Healthcare Trust of America, and it earns rent from a diversified base of healthcare providers whose demand tends to be less cyclical than other property types.

The investment picture centers on funds from operations (FFO), occupancy, and the balance sheet rather than rapid growth. Management has been raising occupancy toward the low-90s percent range, growing same-store cash net operating income, and selling assets to pay down debt, while the dividend (a defining feature of most REITs) provides the bulk of the total-return case. Interest rates matter a great deal here: higher-for-longer rates raise financing costs and pressure REIT valuations, so HR is generally viewed through an income-and-stability lens.

As a REIT, HR is sensitive to interest rates, since higher rates raise borrowing costs and can compress the price investors pay for its cash flows. Its FFO payout leaves limited cushion, and the dividend has been trimmed in the past, so distribution coverage is worth watching. Integration of the large Healthcare Trust of America portfolio, tenant credit and move-outs, and elevated leverage relative to some peers add execution risk. Asset sales used to cut debt can also dilute near-term earnings power. Any broader weakness in commercial real estate values could weigh on the shares.

12 analysts publish price targets on HR, averaging $21.58 against a $19.36 price as of September 2026, or +11.5%. The published targets run from $18.00 to $24.00, a narrow spread, and the ratings split 4 buy, 9 hold, 0 sell. Over the last six months there have been 10 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Healthcare Realty Trust Incorpo. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Occupancy and leasing momentum. HR reported record quarterly leasing of more than 2 million square feet in Q1 2026 and same-store occupancy of about 92.3 percent, up roughly 110 basis points year over year. The most optimistic published target, $24.00, assumes this works close to its best case.

The case against. As a REIT, HR is sensitive to interest rates, since higher rates raise borrowing costs and can compress the price investors pay for its cash flows. The most pessimistic target, $18.00, is roughly what HR is worth if this bites instead.

Read the full bull and bear case on HR, including what would have to change to break either one. Walnut is not an investment adviser.

No. Healthcare Realty Trust Incorpo (HR) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Healthcare Realty Trust Incorpo's investor relations page or your broker.

• Market cap: ~$7.1B
• Revenue (TTM): ~$1.2B
• Normalized FFO/share (Q1 2026): ~$0.41
• FY2026 normalized FFO guidance: ~$1.59-$1.65
• Dividend yield: ~4.7%
• Net debt / adjusted EBITDA: ~5.4x

REITs are usually valued on FFO per share and dividend yield rather than standard price-to-earnings, because large non-cash depreciation charges understate GAAP earnings. HR trades as an income vehicle, with a quarterly dividend near $0.24 per share and a yield in the mid-4-percent range as of mid-2026. Figures are approximate and drawn from recent results and guidance.

Other names that sit close to HR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

HR is a yield-focused healthcare REIT whose story hinges on lifting occupancy, growing same-store cash flow, and paying down debt after its 2022 Healthcare Trust of America merger.

Whether HR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HR a buy or a sell?, and where the stock could go from here in the HR stock forecast.

For income investors, whether HR pays a dividend and how the payout looks is covered in does HR pay a dividend? And to weigh HR against a peer, read the full side-by-side comparisons: HR vs WELL and HR vs VTR.